Direct rotation from a fentanyl patch to a buprenorphine patch in a patient with chronic pain

Naomi Steenhof; John Flannery; Joyce Lee

doi:10.5055/jom.0865

Authors

Naomi Steenhof, RPh, PhD https://orcid.org/0000-0001-7931-9134
John Flannery, MD
Joyce Lee, NP

DOI:

https://doi.org/10.5055/jom.0865

Keywords:

fentanyl, buprenorphine, opioid rotation, chronic pain

Abstract

Transitioning a patient with chronic pain from a fentanyl patch to a buprenorphine patch has not been well described in the literature. Even after a patient removes their fentanyl patch, the residual fentanyl in the skin continues to be absorbed for hours. Due to the risk of precipitated withdrawal when initiating buprenorphine, this transition is a more challenging opioid rotation to plan safely. We report a case of a patient who had been using a fentanyl patch for over 10 years and was successfully rotated directly to a buprenorphine patch.

Author Biographies

Naomi Steenhof, RPh, PhD

Toronto Rehabilitation Institute, University Health Network, University of Toronto, Toronto, Canada

John Flannery, MD

Toronto Rehabilitation Institute, University Health Network, University of Toronto, Toronto, Canada

Joyce Lee, NP

Toronto Rehabilitation Institute, University Health Network, University of Toronto, Toronto, Canada

References

Health Canada: An action plan for pain in Canada. 2021. Available at https://www.canada.ca/content/dam/hc-sc/documents/corporate/about-health-Canada/public-engagement/external-advisory-bodies/canadian-pain-task-force/report-2021-rapport/report-rapport-2021-eng.pdf. Accessed August 1, 2023.

HQO Quality Standards: Chronic pain: Care for adults, adolescents, and children. Available at https://www.hqontario.ca/Portals/0/documents/evidence/quality-standards/qs-chronicpain-quality-standard-en.pdf. Accessed August 1, 2023.

Murphy L, Babaei-Rad R, Buna D, et al.: Guidance on opioid tapering in the context of chronic pain: Evidence, practical advice and frequently asked questions. Can Pharm J. 2018; 151(2): 114-120. DOI: https://doi.org/10.1177/1715163518754918

Chen KY, Chen L, Mao J: Buprenorphine-naloxone therapy in pain management. Anesthesiology. 2014; 120(5): 1262-1274. DOI: https://doi.org/10.1097/ALN.0000000000000170

Jorgenson D, Halpape K: Evaluation of a pharmacist-led interprofessional chronic pain clinic in Canada. Can Pharm J. 2023; 156(5). DOI: 10.1177/17151635231188334. DOI: https://doi.org/10.1177/17151635231188334

Steenhof N, Flannery J, Lee J: Acute pain management for a patient with chronic pain stabilized on buprenorphine-naloxone. NP Curr. 2022; 3: 21-22.

Lee J, Steenhof N: The development of a buprenorphine/ naloxone induction clinic in a tertiary pain clinic. In Canadian Pain Society's 39th Annual Scientific Meeting, Montreal, QC, Canada. 2018.

Center for Effective Practice: Opioid manager, Toronto. 2017. Available at http://cep.health/clinical-products/opioidmanager/. Accessed August 1, 2023.

Chen L, Vo T, Seefeld L, et al.: Lack of correlation between opioid dose adjustment and pain score change in a group of chronic pain patients. J Pain. 2013; 14(4): 384-392. DOI: https://doi.org/10.1016/j.jpain.2012.12.012